All Blogs
Dec 08, 2022
Olympus Launches New Gynecologic Power Morcellator; Journey Biosciences Launched NaviDKD; GE Board Approves Separation of GE HealthCare; FDA Approval to Enovis’s STAR Ankle; FDA Clearance to Deep Blue Medical’s T-Line Hernia Mesh; NeuroOne Completed Feasibility Study with its OneRF Ablation System
Olympus Launches New Gynecologic Power Morcellator for Its Contained Tissue Extraction System On November 30, 2022, Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, launched the moresolution™ Power Morcellator, manufactured by TROKAM...
Read More...
Dec 07, 2022
Navigating the Vital Role of Bioinformatics in Biological Processes and Medicine
Bioinformatics is one of the healthcare industry's most spotlighted and trending topics today. The Bioinformatics market is evolving rapidly and reaching new heights with each passing day, leading to new insights and information into molecular sequence and genomics. Moreover, it makes handling and analyzing genomic...
Read More...
Dec 06, 2022
Nkarta’s Anti-CD19 Allogeneic CAR-NK Cell Therapy, NKX019; Eisai Presents Results of lecanemab for Alzheimer’s Disease; EQRx’s Aumolertinib for EGFR-Mutated NSCLC; FDA Approves Olutasidenib for IDH1-Mutated R/R AML; FDA Orphan Drug Designation to AUM302 for Neuroblastoma; X4 Pharma Announces Results for WHIM Syndrome Drug
FDA Grants Orphan Drug Designation to AUM302 for Neuroblastoma A global clinical-stage biotech company, AUM Biosciences, focused on discovering and developing precision oncology therapeutics, declared that the U.S. FDA has permitted Orphan Drug Designation for AUM302. For the treatment of neuroblastoma, AUM302 i...
Read More...
Oct 04, 2024
Which Key Player Holds the Potential to Corner the Rheumatoid Arthritis Therapeutics Market?
Rheumatoid Arthritis is a chronic, inflammatory autoimmune disease that leads to progressive and destructive polyarthritis and affects approximately 1% of the population. The rheumatoid arthritis population is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joi...
Read More...
Dec 02, 2022
PD-1 and PD-L1 Inhibitors: Will They Dominate Over Conventional Cancer Therapies?
The development of tumor therapy in cancer immunotherapy has been aided by programmed death receptor-1 and programmed death protein ligand inhibitors. Since its discovery in 1990, the programmed cell death protein 1 receptor (PD-1) receptor has been known to negatively regulate T-cell mediated immune response via i...
Read More...
Dec 01, 2022
AnchorDx’s UriFind Bladder Cancer Assay in the US; UroMems Initiates Smart Implant to Treat Stress Urinary Incontinence; FDA 510(k) Clearance to NeuroLogica’s BodyTom 64; CE-IVD Mark Approval to SeekInCure’s Recurrence Monitoring Kit Gets; Ypsomed and CamDiab’s Automated Insulin Dosing System; Boston Scientific to Acquire Apollo Endosurgery
AnchorDx Clinical Trial Enrols First Patient for its UriFind® Bladder Cancer Assay in the US On November 23, 2022, AnchorDx, announced the first patient enrollment for its clinical trials of the UriFind® bladder cancer assay in the United States. The UriFind® bladder cancer assay clinical trial in the U...
Read More...
Nov 30, 2022
Key Insights and Analysis Into the Point of Care Diagnostics Market
In recent years, the healthcare industry has witnessed immense growth in the screening and diagnostics segment. The incorporation of new-age technologies is bringing several life-saving revolutions to the market and improving the overall health outcomes for the patient. Digitization, innovation, newer hybrid busine...
Read More...
Nov 30, 2022
Antibody-Drug Conjugate: The Smart Biological Bomb
Antibody-drug conjugate (ADCs) is a new emerging class of highly potent pharmaceutical drugs, which is a great combination of chemotherapy and immunotherapy. Over the past couple of decades, antibody-drug conjugates have revolutionized the field of cancer chemotherapy. ADCs are composed of 3 parts: an antibody drug...
Read More...
Nov 29, 2022
C4X Discovery and AstraZeneca Signs Deal; FDA Rejects Spectrum’s Poziotinib; Orphan Drug Designation to Tenaya’s Gene Therapy; EC Approves Regeneron’s Libtayo; Response Letter to Poziotinib for Metastatic NSCLC Harboring HER2 Exon 20 Mutations; Japan Approves Trastuzumab Deruxtecan for HER2+ Breast Cancer
C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License C4X Discovery Holdings has signed an exclusive global license with AstraZeneca worth up to USD 402 million for the development and commercialization of the NRF2 Activator program. The agreement will allow AstraZeneca to develop...
Read More...
Nov 28, 2022
Nascent Advancements and Emerging Therapies in Chronic Pulmonary Hypertension Treatment Market
Chronic pulmonary hypertension (CPH) encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance, accounting for approximately 42 million cases in 7MM in 2021. As per DelveInsight’s analysis, the 7MM prevalence is expected to increase at a considerable CAGR of 0....
Read More...